Cargando…

Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study

(1) Background: Efavirenz plasma concentration displays wide between-patient variability partly due to pharmacogenetic variation and autoinduction. Pediatric data on efavirenz pharmacokinetics and the relevance of pharmacogenetic variation are scarce, particularly from sub-Saharan Africa, where >...

Descripción completa

Detalles Bibliográficos
Autores principales: Chala, Adugna, Tadesse, Birkneh Tilahun, Chaka, Tolossa Eticha, Mukonzo, Jackson, Kitabi, Eliford Ngaimisi, Tadesse, Sintayehu, Pohanka, Anton, Makonnen, Eyasu, Aklillu, Eleni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707067/
https://www.ncbi.nlm.nih.gov/pubmed/34945777
http://dx.doi.org/10.3390/jpm11121303
_version_ 1784622346226630656
author Chala, Adugna
Tadesse, Birkneh Tilahun
Chaka, Tolossa Eticha
Mukonzo, Jackson
Kitabi, Eliford Ngaimisi
Tadesse, Sintayehu
Pohanka, Anton
Makonnen, Eyasu
Aklillu, Eleni
author_facet Chala, Adugna
Tadesse, Birkneh Tilahun
Chaka, Tolossa Eticha
Mukonzo, Jackson
Kitabi, Eliford Ngaimisi
Tadesse, Sintayehu
Pohanka, Anton
Makonnen, Eyasu
Aklillu, Eleni
author_sort Chala, Adugna
collection PubMed
description (1) Background: Efavirenz plasma concentration displays wide between-patient variability partly due to pharmacogenetic variation and autoinduction. Pediatric data on efavirenz pharmacokinetics and the relevance of pharmacogenetic variation are scarce, particularly from sub-Saharan Africa, where >90% of HIV-infected children live and population genetic diversity is extensive. We prospectively investigated the short- and long-term effects of efavirenz auto-induction on plasma drug exposure and the influence of pharmacogenetics among HIV-infected Ethiopian children. (2) Method: Treatment-naïve HIV-infected children aged 3–16 years old (n = 111) were enrolled prospectively to initiate efavirenz-based combination antiretroviral therapy (cART). Plasma efavirenz concentrations were quantified at 4, 8, 12, 24, and 48 weeks of cART. Genotyping for CYP2B6, CYP3A5, UGT2B7, ABCB1, and SLCO1B1 common functional variant alleles was performed. (3) Results: The efavirenz plasma concentration reached a peak at two months, declined by the 3rd month, and stabilized thereafter, with no significant difference in geometric mean over time. On average, one-fourth of the children had plasma efavirenz concentrations ≥4 µg/mL. On multivariate analysis, CYP2B6*6 and ABCB1c.3435 C > T genotypes and low pre-treatment low-density lipoprotein (LDL) were significantly associated with higher plasma efavirenz concentration regardless of treatment duration. Duration of cART, sex, age, nutritional status, weight, and SLCO1B, CYP3A5, UGT2B7, and ABCB1 rs3842 genotypes were not significant predictors of efavirenz plasma exposure. (4) Conclusion: Pre-treatment LDL cholesterol and CYP2B6*6 and ABCB1c.3435 C > T genotypes predict efavirenz plasma exposure among HIV-infected children, but treatment-duration-dependent changes in plasma efavirenz exposure due to auto-induction are not statistically significant.
format Online
Article
Text
id pubmed-8707067
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87070672021-12-25 Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study Chala, Adugna Tadesse, Birkneh Tilahun Chaka, Tolossa Eticha Mukonzo, Jackson Kitabi, Eliford Ngaimisi Tadesse, Sintayehu Pohanka, Anton Makonnen, Eyasu Aklillu, Eleni J Pers Med Article (1) Background: Efavirenz plasma concentration displays wide between-patient variability partly due to pharmacogenetic variation and autoinduction. Pediatric data on efavirenz pharmacokinetics and the relevance of pharmacogenetic variation are scarce, particularly from sub-Saharan Africa, where >90% of HIV-infected children live and population genetic diversity is extensive. We prospectively investigated the short- and long-term effects of efavirenz auto-induction on plasma drug exposure and the influence of pharmacogenetics among HIV-infected Ethiopian children. (2) Method: Treatment-naïve HIV-infected children aged 3–16 years old (n = 111) were enrolled prospectively to initiate efavirenz-based combination antiretroviral therapy (cART). Plasma efavirenz concentrations were quantified at 4, 8, 12, 24, and 48 weeks of cART. Genotyping for CYP2B6, CYP3A5, UGT2B7, ABCB1, and SLCO1B1 common functional variant alleles was performed. (3) Results: The efavirenz plasma concentration reached a peak at two months, declined by the 3rd month, and stabilized thereafter, with no significant difference in geometric mean over time. On average, one-fourth of the children had plasma efavirenz concentrations ≥4 µg/mL. On multivariate analysis, CYP2B6*6 and ABCB1c.3435 C > T genotypes and low pre-treatment low-density lipoprotein (LDL) were significantly associated with higher plasma efavirenz concentration regardless of treatment duration. Duration of cART, sex, age, nutritional status, weight, and SLCO1B, CYP3A5, UGT2B7, and ABCB1 rs3842 genotypes were not significant predictors of efavirenz plasma exposure. (4) Conclusion: Pre-treatment LDL cholesterol and CYP2B6*6 and ABCB1c.3435 C > T genotypes predict efavirenz plasma exposure among HIV-infected children, but treatment-duration-dependent changes in plasma efavirenz exposure due to auto-induction are not statistically significant. MDPI 2021-12-05 /pmc/articles/PMC8707067/ /pubmed/34945777 http://dx.doi.org/10.3390/jpm11121303 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chala, Adugna
Tadesse, Birkneh Tilahun
Chaka, Tolossa Eticha
Mukonzo, Jackson
Kitabi, Eliford Ngaimisi
Tadesse, Sintayehu
Pohanka, Anton
Makonnen, Eyasu
Aklillu, Eleni
Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study
title Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study
title_full Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study
title_fullStr Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study
title_full_unstemmed Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study
title_short Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study
title_sort predictors of efavirenz plasma exposure, auto-induction profile, and effect of pharmacogenetic variations among hiv-infected children in ethiopia: a prospective cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707067/
https://www.ncbi.nlm.nih.gov/pubmed/34945777
http://dx.doi.org/10.3390/jpm11121303
work_keys_str_mv AT chalaadugna predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy
AT tadessebirknehtilahun predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy
AT chakatolossaeticha predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy
AT mukonzojackson predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy
AT kitabielifordngaimisi predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy
AT tadessesintayehu predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy
AT pohankaanton predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy
AT makonneneyasu predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy
AT aklillueleni predictorsofefavirenzplasmaexposureautoinductionprofileandeffectofpharmacogeneticvariationsamonghivinfectedchildreninethiopiaaprospectivecohortstudy